283 related articles for article (PubMed ID: 28720060)
1. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
[TBL] [Abstract][Full Text] [Related]
2. β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.
Bleckmann A; Conradi LC; Menck K; Schmick NA; Schubert A; Rietkötter E; Arackal J; Middel P; Schambony A; Liersch T; Homayounfar K; Beißbarth T; Klemm F; Binder C; Pukrop T
Clin Exp Metastasis; 2016 Apr; 33(4):309-23. PubMed ID: 26862065
[TBL] [Abstract][Full Text] [Related]
3. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
5. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer.
Davol PA; Bagdasaryan R; Elfenbein GJ; Maizel AL; Frackelton AR
Cancer Res; 2003 Oct; 63(20):6772-83. PubMed ID: 14583473
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
Kimbung S; Johansson I; Danielsson A; Veerla S; Egyhazi Brage S; Frostvik Stolt M; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmström PO; Söderberg M; Walz TM; Fernö M; Hatschek T; Hedenfalk I;
Clin Cancer Res; 2016 Jan; 22(1):146-57. PubMed ID: 26276891
[TBL] [Abstract][Full Text] [Related]
7. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
[TBL] [Abstract][Full Text] [Related]
8. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.
Kimbung S; Kovács A; Bendahl PO; Malmström P; Fernö M; Hatschek T; Hedenfalk I
Mol Oncol; 2014 Feb; 8(1):119-28. PubMed ID: 24287398
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
10. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
11. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
12. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease.
Gong DH; Fan L; Chen HY; Ding KF; Yu KD
Oncotarget; 2016 May; 7(19):28570-8. PubMed ID: 27086913
[TBL] [Abstract][Full Text] [Related]
14. Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer.
Woodman N; Pinder SE; Tajadura V; Le Bourhis X; Gillett C; Delannoy P; Burchell JM; Julien S
Int J Oncol; 2016 Jul; 49(1):265-75. PubMed ID: 27176937
[TBL] [Abstract][Full Text] [Related]
15. PPFIA1 and CCND1 are frequently coamplified in breast cancer.
Dancau AM; Wuth L; Waschow M; Holst F; Krohn A; Choschzick M; Terracciano L; Politis S; Kurtz S; Lebeau A; Friedrichs K; Wencke K; Monni O; Simon R
Genes Chromosomes Cancer; 2010 Jan; 49(1):1-8. PubMed ID: 19787783
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
17. Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index.
Liu MT; Huang WT; Wang AY; Huang CC; Huang CY; Chang TH; Pi CP; Yang HH
Support Care Cancer; 2010 Dec; 18(12):1553-64. PubMed ID: 19904562
[TBL] [Abstract][Full Text] [Related]
18. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
20. A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen.
Wang K; Li J; Xiong YF; Zeng Z; Zhang X; Li HY
Sci Rep; 2018 Feb; 8(1):3179. PubMed ID: 29453409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]